Bisphosphonates are currently used in the treatment of many diseases involving increased bone resorption such as osteoporosis. Statins have been widely used for the treatment of hypercholesterolemia and recent studies have shown that these drugs are also capable of stimulating bone formation. The purpose of this study was to evaluate the influence of an estrogen deficient state and the effects ...

OBJECTIVE Zoledronic acid and denosumab were funded by the Australian government for the management of osteoporosis at an equivalent price to alendronate. The price of alendronate has declined by around 65 %, but the price of the other two therapies has remained stable. Using data published since the listing, this paper reports current estimates of the value of denosumab compared to alendronate...

We previously reported that squalestatin 1-mediated induction of CYP2B expression is attributable to squalene synthase inhibition and accumulation of an endogenous isoprenoid(s) that is capable of activating the constitutive androstane receptor. To determine whether squalestatin 1-mediated CYP2B induction is strictly dependent on the biosynthesis of farnesyl pyrophosphate (FPP), the substrate f...

INTRODUCTION Osteoclastic activity is required for orthodontic force to move teeth through alveolar bone. Bisphosphonates are drugs that inhibit osteoclast maturation, function, and survival. The aim of this study was to assess orthodontic tooth movement in rats receiving bisphosphonate treatment. METHODS Two groups of Sprague-Dawley rats were used. The rats in the treatment group received 7 ...

The title compound {sys-tematic name: bis(μ(2)-dihydrogen 4-aza-niumyl-1-hy-droxy-butane-1,1-di-phos-pho-n-ato)bis-[aqua-(dihydrogen 4-aza-nium-yl-1-hy-droxy-butane-1,1-diphospho-n-ato)nickel(II)] dihydrate}, [Ni(2)(C(4)H(12)NO(7)P(2))(4)(H(2)O)(2)]·2H(2)O, was synthesiized under hydro-thermal conditions. Its structure is isotypic with the Co(II) analogue. The crystal structure is built up from...

Alendronate is used as first-line treatment for osteoporosis in postmenopausal women worldwide. The evidence supporting its benefit in reducing the risk of fragility fracture among this high-risk group is well established. Due to its mechanism of action, there were concerns about potential reduction in bone turnover, repair of microdamage and hence reduced bone toughness and increased risk of f...

BACKGROUND Studies concerning prognostic factors specific for alendronate-related osteonecrosis of the jaws (ONJ) are rare. METHODS We surveyed a cohort of 100 osteoporotic patients with 111 alendronate-related ONJ lesions treated during a 4-year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses. RESULTS ...

BACKGROUND The arterial hypertension is a disorder characterized by relevant alterations in the bone tissue. The sodium alendronate is indicated in the treatment of bone diseases, because of its affinity with the hydroxyapatite, inhibiting the bone reabsorptions. OBJECTIVE To analyze local action of the sodium alendronate in the bone repair of spontaneously hypertensive rat (SHR). METHODS A...

The objective of the present study was to evaluate the effect of 17beta-estradiol or alendronate in preventing bone loss in 3-month-old ovariectomized Wistar rats. One group underwent sham ovariectomy (control, N = 10), and the remaining three underwent double ovariectomy. One ovariectomized group did not receive any treatment (OVX, N = 12). A second received subcutaneous 17beta-estradiol at a ...

Osteoporosis is a common and debilitating condition associated with significant morbidity and mortality. The efficacy and safety of oral bisphosphonates for the treatment of osteoporosis are well established. However, patient adherence and persistence on treatment are suboptimal. This randomised open-label multi-centre study of 6-months' duration compared persistence on treatment in postmenopau...